Hovon

Recent papers from Hovon

1. Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-RBlood Cancer Journal · 2026
2. The immunophenotypic landscape of newly diagnosed acute myeloid leukemia: Associations with genotype and outcomesiScience · 2026
3. Feasibility of a prospective real-time monitoring system capturing real-world data from elderly patients with acute myeloid leukemiaESMO Real World Data and Digital Oncology · 2026
4. Impact of Vincristine Dose Reduction on Outcomes of Patients With Advanced‐Stage Diffuse Large B‐Cell Lymphoma Treated With R‐ CHOPEuropean Journal Of Haematology · 2026
5. Targeting Cancer Cells With Self‐Assembled Ru‐Polysaccharide Photocatalyst for Visible‐Light‐Induced Activation of ProdrugsChemistry - A European Journal · 2026
6. Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphomaCell Reports Medicine · 2026
7. Flow‐Enabled Direct Photochemical Functionalization of Aryl FluoridesAdvanced Synthesis & Catalysis · 2026
8. Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphomaJournal for ImmunoTherapy of Cancer · 2026
9. Escaping the Iron Law of Electrochemical CO ₂ Reduction Using Pd ₁₂ L ₂₄ Cages as Artificial 2nd Coordination SpheresInorganic Chemistry · 2026
10. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patientsBlood Cancer Journal · 2026
11. Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studiesHemaSphere · 2026
12. Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyHaematologica · 2026
13. Evaluating the demographic impacts of the highly pathogenic avian influenza panzootic2026
14. Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B‐Cell Non‐Hodgkin LymphomaAmerican Journal of Hematology · 2026
15. Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemiaBlood Neoplasia · 2026
16. MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesBlood Advances · 2026
17. Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell LymphomaJournal of Clinical Oncology · 2025
18. Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemiaLeukemia · 2025
19. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaNew England Journal of Medicine · 2025
20. Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcomeHemaSphere · 2025